StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$35.91−0.53 (-1.45%)

Close on Nov 17, 2026Market cap $1.23BP/E –Yield –

Nektar Therapeutics cash

Cash and short-term investments held at the end of each period.

Nektar Therapeutics's cash was $684.34M at Jun 30, 2026. For fiscal 2025 it was $245.75M, down 3.7% from the year before. Over ten years it grew 16.0% a year on average. The highest annual figure on record is $1.34B in fiscal 2018.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$245.75M-3.7%
FY2024Dec 31, 2024$255.23M-15.9%
FY2023Dec 31, 2023$303.62M-39.9%
FY2022Dec 31, 2022$504.98M-31.2%
FY2021Dec 31, 2021$733.96M-30.9%
FY2020Dec 31, 2020$1.06B-19.8%
FY2019Dec 31, 2019$1.32B-0.8%
FY2018Dec 31, 2018$1.34B+350.9%
FY2017Dec 31, 2017$296.13M+396.5%
FY2016Dec 31, 2016$59.64M+7.3%
FY2015Dec 31, 2015$55.57M+349.4%
FY2014Dec 31, 2014$12.37M-68.3%
FY2013Dec 31, 2013$39.07M+53.6%
FY2012Dec 31, 2012$25.44M-93.9%
FY2011Dec 31, 2011$414.90M+2236.8%
FY2010Dec 31, 2010$17.76M-64.2%
FY2009Dec 31, 2009$49.60M-68.1%
FY2008Dec 31, 2008$155.58M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$684.34M+213.0%
Q4 FY2025Dec 31, 2025$245.75M-3.7%
Q3 FY2025Sep 30, 2025$270.21M+10.5%
Q2 FY2025Jun 30, 2025$175.90M-35.1%
Q1 FY2025Mar 31, 2025$218.63M-24.4%
Q4 FY2024Dec 31, 2024$255.23M-15.9%
Q3 FY2024Sep 30, 2024$244.50M-34.4%
Q2 FY2024Jun 30, 2024$271.24M-33.8%
Q1 FY2024Mar 31, 2024$289.24M-36.7%
Q4 FY2023Dec 31, 2023$303.62M-39.9%
Q3 FY2023Sep 30, 2023$372.66M-31.8%
Q2 FY2023Jun 30, 2023$409.43M-33.9%
Q1 FY2023Mar 31, 2023$456.83M-31.5%
Q4 FY2022Dec 31, 2022$504.98M-31.2%
Q3 FY2022Sep 30, 2022$546.39M-40.7%
Q2 FY2022Jun 30, 2022$619.32M-38.1%
Q1 FY2022Mar 31, 2022$667.03M-35.7%
Q4 FY2021Dec 31, 2021$733.96M-30.9%
Q3 FY2021Sep 30, 2021$921.08M-3.7%
Q2 FY2021Jun 30, 2021$1.00B-3.7%
Q1 FY2021Mar 31, 2021$1.04B-22.9%
Q4 FY2020Dec 31, 2020$1.06B-19.8%
Q3 FY2020Sep 30, 2020$956.01M-36.1%
Q2 FY2020Jun 30, 2020$1.04B-31.5%
Q1 FY2020Mar 31, 2020$1.35B-3.1%
Q4 FY2019Dec 31, 2019$1.32B-0.8%
Q3 FY2019Sep 30, 2019$1.50B+5.3%
Q2 FY2019Jun 30, 2019$1.52B+66.3%
Q1 FY2019Mar 31, 2019$1.39B+3889.8%
Q4 FY2018Dec 31, 2018$1.34B+350.9%
Q3 FY2018Sep 30, 2018$1.42B+3641.2%
Q2 FY2018Jun 30, 2018$911.13M+5542.0%
Q1 FY2018Mar 31, 2018$34.81M+48.2%
Q4 FY2017Dec 31, 2017$296.13M+396.5%
Q3 FY2017Sep 30, 2017$37.97M-40.0%
Q2 FY2017Jun 30, 2017$16.15M-71.0%
Q1 FY2017Mar 31, 2017$23.48M–
Q4 FY2016Dec 31, 2016$59.64M–
Q3 FY2016Sep 30, 2016$63.30M–
Q2 FY2016Jun 30, 2016$55.68M–

More Nektar Therapeutics figures

See a number that looks wrong?